<DOC>
	<DOCNO>NCT00117234</DOCNO>
	<brief_summary>The purpose study evaluate effect treatment darbepoetin alfa peak oxygen consumption ( peak VO2 ) subject symptomatic CHF anemia .</brief_summary>
	<brief_title>Impact Darbepoetin Alfa Exercise Tolerance Left Ventricular Structure Subjects With Symptomatic Congestive Heart Failure ( CHF ) Anemia</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Symptomatic CHF least 3 month Reduced leave ventricular ejection fraction Stable heart failure medication Peak VO2 less equal 16 ml/kg/min Hemoglobin concentration 9.0 12.0 g/dL Hypertension Unstable angina pectoris recent myocardial infarction Likely receive cardiac transplant Unable cardiopulmonary exercise test Major organ transplant ( e.g. , lung , liver , heart ) renal replacement therapy ( e.g. , dialysis ) Recent current treatment malignancy Systemic hematologic disease Anemia due acute chronic bleed Recent EpogenÂ® darbepoetin alfa therapy Recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>chronic heart failure</keyword>
	<keyword>congestive heart failure</keyword>
	<keyword>low hemoglobin</keyword>
	<keyword>anemia</keyword>
	<keyword>CHF</keyword>
	<keyword>Symptomatic Congestive Heart Failure ( CHF )</keyword>
</DOC>